On April 4, 2024 Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB) ("Sirona") reported that it has closed its private placement (Private Placement") for gross proceeds of $132,500 CAD. The Private Placement consists of 1,325,000 units, (the "Units") at a price of $0.10 per Unit (Press release, Sirona Biochem, APR 4, 2024, View Source;utm_medium=rss&utm_campaign=sirona-biochem-announces-close-of-private-placement [SID1234641816]). Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of issue at a price of $0.15 per Share in year one and $0.25 per Share in year two. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024.
Proceeds will be used for general working capital purposes.
No insiders participated in the Private Placement.
No finders’ fees were paid from the Private Placement.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On April 4, 2024 Huahui Health Ltd.("Huahui Health"), a clinical stage biotechnology company focused on discovering and developing virology, hepatology, and oncology therapies, reported that it will present the results of preclinical data of HH018-sesutecan, a tumor microenvironment targeting CD98-directed ADC, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024 (Press release, Huahui Health, APR 4, 2024, View Source [SID1234641809]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The AACR (Free AACR Whitepaper) meeting will be held April 5–10, 2024, in San Diego, California.

Topic: A tumor microenvironment-targeting CD98-directed ADC confers robust anti-tumor activity in multiple cancers with favorable pharmacokinetics and safety profiles in preclinical models

Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 4
Session Date and Time: Wednesday Apr 10, 2024 9:00 AM – 12:30 PM
Location: Poster Section 54
Poster Board Number: 1
Abstract Presentation Number: LB425
Presenter: Bin Chen, CEO of Huahui Health. Zhu Chen, CSO of ProfoundBio

On April 4, 2024 Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, reported data from a pilot study demonstrating the potential of a simple PCR assay based on EpiCheck technology to accurately differentiate between small cell lung cancer (SCLC) subtypes (Press release, Nucleix, APR 4, 2024, View Source [SID1234641808]). The Company is presenting the data in a poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024 in San Diego, April 5-10.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 13-marker PCR assay developed for this pilot study stemmed from data from a recent study published in Cancer Cell demonstrating the detection of SCLC using DNA methylation in plasma samples from heavy smokers, yielding a sensitivity of 94% and specificity of 95%. Based on the strength of these results, Nucleix collaborated with The University of Texas MD Anderson Cancer Center to develop novel biomarkers for the classification of SCLC into subtypes to reduce time between diagnosis and tailored treatment interventions. In the data being presented at AACR (Free AACR Whitepaper), the 13-marker PCR assay correctly classified 97% of the SCLC tissue samples in a blinded cohort.

"For decades, SCLC was considered a single, monolithic entity resulting in our current clinical protocols being based on disease stage, with no consideration of biomarkers that have predictive or prognostic significance, leading to expectedly poor outcomes," said Mathias Ehrich, M.D., chief scientific officer. "These data show that we can potentially reduce the time between patient diagnosis and initiation of tailored treatment or inclusion in clinical studies from a month, in best-case scenarios, to just a few days, by using our PCR EpiCheck-based assay for the classification of SCLC subtypes."

Details of the AACR (Free AACR Whitepaper) presentation are as follows:

Title: "Subtype classification of small cell lung cancer (SCLC) tissues using the EpiCheck methylation sensitive restriction-based PCR platform"
Session Title: Epigenetic Targets in Oncology
Session Date and Time: Monday, April 8, 9:00 AM – 12:30 PM PT
Session Type: Poster Presentation
Abstract / Poster Number: 1722 / 7

On April 4, 2024 Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, reported preclinical data releases for two of their compounds inhibiting the DNA-damage response (DDR) of cancer cells, including Debio 0123 [selective WEE1 inhibitor] and Debio 0432 [Selective USP1 Inhibitor] at the 2024 Annual American Association for Cancer Research (AACR) (Free AACR Whitepaper) summit in San Diego, California (Press release, Debiopharm, APR 4, 2024, View Source [SID1234641807]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Since 2017, Debiopharm has been growing its expertise in the DDR inhibitor field, firstly through its WEE1-inhibitor Debio 0123 and through the recently in-licensed asset, targeting USP1. These posters are proof of our commitment to stay at the forefront of DDR-inhibitor development and outsmart hard-to-treat cancers through synthetic lethality or other groundbreaking combinations." – Angela Zubel, Chief Development Officer at Debiopharm

AACR 2024 Poster Presentations

Debiopharm compound

Title

Presenter

Mon, April 8th
Poster display: 9:00-12:30pm

Abstract #: CT064

Poster Section: 48

Poster Board #: 14

Debio 0123

Impact of food and high gastric pH on the bioavailability of the WEE1 inhibitor Debio 0123 assessed in a

Phase 1 dose escalation study

Anne Bellon, Clinical Pharmacology Lead

Mon, April 8th
Poster display: 1:30-5:00pm

Abstract #: 3370

Poster Section: 29

Poster Board #: 27

Debio 0123

Anti-tumor activity of Debio 0123 in combination with sacituzumab govitecan in preclinical models of breast cancer

Luke Piggott, Principal Scientist

Tue, April 9th
Poster display: 1:30-5:00pm

Abstract #: 6507

Poster Section: 46

Poster Board #: 24

Debio 0123

Simulation driven identification of combination for the WEE1 inhibitor Debio 0123 results in synergistic effect with cabozantinib validated in vivo

Luke Piggott, Principal Scientist

& Turbine AI

Wed, April 10th
Poster display: 9:00-12:30pm

Abstract #: 7145

Poster Section: 23

Poster Board #: 7

Debio 0432

Identification of Debio 0432 as a potent and selective USP1 inhibitor for cancer therapy

Noemie Luong, Associate Principal Scientist

About DNA-Damage Repair (DDR)

When cells have damaged DNA, they need to undergo a repair process called DDR to be able to survive. Cancer cells rely a lot on DDR as they divide and grow uncontrollably. Inhibition of DDR, particularly in combination with other anticancer agents, prevents cancer cells from repairing their DNA, which ultimately activates a self-destruction program in cancer cells. DDR inhibitors such as Debiopharm’s WEE1 and USP1 inhibitors, are being tested in clinical and preclinical studies.

On April 3, 2024 NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production, and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, reported that Frank Scholz, Ph.D., President and Chief Executive Officer will present at the upcoming 2024 Jefferies Radiopharma Innovation Summit (Press release, NorthStar Medical Radiostopes, APR 4, 2024, View Source [SID1234641806]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:
Date: April 11, 2024
Time: 3:35 – 4:05 p.m. EDT
Location: Jefferies Conference Center, NYC, New York

"2024 and the next several years are pivotal for NorthStar as we expand our capabilities in the rapidly growing radiopharmaceuticals industry," said Frank Scholz, Ph.D., President and Chief Executive Officer of NorthStar Medical Radioisotopes. "We believe the industry is on the cusp of a global paradigm shift in the development and commercialization of effective new radiotherapies, and we believe our ability to produce medical radioisotopes at scale, coupled with the build-out of our radiopharmaceutical contract development and manufacturing services (CDMO/CMO services) on the same campus can be a key catalyst of this change."

"Today we are routinely producing therapeutic copper-67 that is used in on-going clinical trials," Scholz continued, "and are poised to be one of the first commercial-scale producers of non-carrier-added (n.c.a.) actinium-225 globally. Our radiopharmaceutical R&D lab is busy with both PET diagnostics and therapeutics work where sponsors are experiencing useful results as they work to improve upon their formulations and processes. NorthStar is strongly positioned for continued rapid growth in key areas of our industry, and we look forward to sharing information about our plans and future with the investor community at the upcoming Jefferies Radiopharma Innovation Summit."

Dr. Scholz and Paul Estrem, Executive Vice President and Chief Financial Officer, will also be available during the conference for one-on-one meetings. Please reach out to your Jefferies representative to schedule.